Abstract
High levels of BCL-2 family proteins are implicated in a failed/ineffective apoptotic programme, often resulting in diseases, including cancer. Owing to their potential as drug targets in cancer therapy, several inhibitors of BCL-2 family proteins have been developed. These primarily target specific members of the BCL-2 family, particularly BCL-2 and BCL-XL but are ineffective against MCL-1. Major efforts have been invested in developing inhibitors of MCL-1, which is commonly amplified in human tumours and associated with tumour relapse and chemoresistance. In this report, the specificity of several BCL-2 family inhibitors (ABT-263, UCB-1350883, apogossypol and BH3I-1) was investigated and compared with putative MCL-1 inhibitors designed to exhibit improved or selective binding affinities for MCL-1 (TW-37, BI97C1, BI97C10, BI112D1, compounds 6 and 7, and MCL-1 inhibitor molecule (MIM-1)). ABT-263, BI97C1, BI112D1, MIM-1 and TW-37 exhibited specificity in inducing apoptosis in a Bax/Bak- and caspase-9-dependent manner, whereas the other agents showed no killing activity, or little or no specificity. Of these inhibitors, only ABT-263 and UCB-1350883 induced apoptosis in a BCL-2- or BCL-XL-dependent system. In cells that depend on MCL-1 for survival, ABT-263 and TW-37 induced extensive apoptosis, suggesting that at high concentrations these inhibitors have the propensity to inhibit MCL-1 in a cellular context. TW-37 induced apoptosis, assessed by chromatin condensation, caspase processing and phosphatidylserine externalisation, in a BAK-dependent manner and in cells that require MCL-1 for survival. TW-37-mediated apoptosis was also partly dependent on NOXA, suggesting that derivatives of TW-37, if engineered to exhibit better selectivity and efficacy at low nanomolar concentrations, may provide useful lead compounds for further synthetic programmes. Expanded medicinal chemistry iteration, as performed for the ABT series, may likewise improve the potency and specificity of the evaluated MCL-1 inhibitors.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- CLL:
-
chronic lymphocytic leukaemia
- MEFs:
-
mouse embryonic fibroblasts
- PARP:
-
poly(ADP-ribose) polymerase
- SAHBs:
-
stabilised alpha-helix of BCL-2 domains
References
Adams JM, Cory S . The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324–1337.
Youle RJ, Strasser A . The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47–59.
Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294–1305.
Lessene G, Czabotar PE, Colman PM . BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7: 989–1000.
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677–681.
Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421–3428.
van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389–399.
Vogler M, Dinsdale D, Dyer MJ, Cohen GM . Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009; 16: 360–367.
Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009; 16: 1030–1039.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202–208.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899–905.
Dai Y, Grant S . Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 2007; 67: 2908–2911.
Gores GJ, Kaufmann SH . Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev 2012; 26: 305–311.
Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 2011; 30: 1963–1968.
Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104: 19512–19517.
Bernardo PH, Sivaraman T, Wan KF, Xu J, Krishnamoorthy J, Song CM et al. Structural insights into the design of small molecule inhibitors that selectively antagonize Mcl-1. J Med Chem 2010; 53: 2314–2318.
Wang Z, Song W, Aboukameel A, Mohammad M, Wang G, Banerjee S et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 2008; 123: 958–966.
Wei J, Kitada S, Rega MF, Stebbins JL, Zhai D, Cellitti J et al. Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 2009; 52: 4511–4523.
Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, Rega MF et al. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 2010; 53: 4166–4176.
Wei J, Stebbins JL, Kitada S, Dash R, Zhai D, Placzek WJ et al. An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins. Front Oncol 2011; 1: 28.
Cohen NA, Stewart ML, Gavathiotis E, Tepper JL, Bruekner SR, Koss B et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem Biol 2012; 19: 1175–1186.
Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488–496.
Porter J, Payne A, de Candole B, Ford D, Hutchinson B, Trevitt G et al. Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors. Bioorg Med Chem Lett 2009; 19: 230–233.
Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK et al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci USA 2011; 108: 8785–8790.
Lugovskoy AA, Degterev AI, Fahmy AF, Zhou P, Gross JD, Yuan J et al. A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors. J Am Chem Soc 2002; 124: 1234–1240.
Gottschalk AR, Boise LH, Oltvai ZN, Accavitti MA, Korsmeyer SJ, Quintans J et al. The ability of Bcl-x(L) and Bcl-2 to prevent apoptosis can be differentially regulated. Cell Death Differ 1996; 3: 113–118.
Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A . Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112–121.
Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P et al. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 2008; 15: 820–830.
Vogler M, Furdas SD, Jung M, Kuwana T, Dyer MJ, Cohen GM . Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res 2010; 16: 4217–4225.
Song L, Coppola D, Livingston S, Cress D, Haura EB . Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 2005; 4: 267–276.
Warr MR, Shore GC . Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 2008; 8: 138–147.
Craxton A, Butterworth M, Harper N, Fairall L, Schwabe J, Ciechanover A et al. NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1. Cell Death Differ 2012; 19: 1424–1434.
Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173–1186.
Goff DJ, Recart AC, Sadarangani A, Chun HJ, Barrett CL, Krajewska M et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 2013; 12: 316–328.
Hogdal LJ, Letai A . BCL-2 inhibition: stemming the tide of myeloid malignancies. Cell Stem Cell 2013; 12: 269–270.
Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013; 12: 329–341.
Bertin-Ciftci J, Barre B, Le Pen J, Maillet L, Couriaud C, Juin P et al. pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737. Cell Death Differ 2013; 20: 755–764.
Stewart ML, Fire E, Keating AE, Walensky LD . The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 2010; 6: 595–601.
Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004; 305: 1466–1470.
LaBelle JL, Katz SG, Bird GH, Gavathiotis E, Stewart ML, Lawrence C et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest 2012; 122: 2018–2031.
Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol 2012; 14: 575–583.
Varadarajan S, Bampton ET, Smalley JL, Tanaka K, Caves RE, Butterworth M et al. A novel cellular stress response characterised by a rapid reorganisation of membranes of the endoplasmic reticulum. Cell Death Differ 2012; 19: 1896–1907.
Varadarajan S, Butterworth M, Wei J, Pellecchia M, Dinsdale D, Cohen GM . Sabutoclax (BI97C1) and BI112D1, Putative Inhibitors of MCL-1, Induce Mitochondrial Fragmentation Either Upstream of or Independent of Apoptosis. Neoplasia 2013; 15: 568–578.
Acknowledgements
We thank Professors Boise, Letai, Mak, Pritchard, Schulze-Osthoff and Strasser for cells. We thank Drs. Maurizio Pellecchia and Jun Wei (Sanford-Burnham Institute, La Jolla, CA, USA) for apogossypol, BI97C1, BI97C10 and BI112D1 and Dr. Christina Chai (Agency for Science Technology and Research, Singapore) for compounds 6 and 7. We also thank Dr. A Payne (UCB Celltech, Slough, UK) for UCB-1350883, Tim Smith and Maria Guerra Martin for technical assistance and the Medical Research Council for core support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Edited by C Borner
Supplementary Information accompanies this paper on Cell Death and Differentiation website
Supplementary information
Rights and permissions
About this article
Cite this article
Varadarajan, S., Vogler, M., Butterworth, M. et al. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ 20, 1475–1484 (2013). https://doi.org/10.1038/cdd.2013.79
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/cdd.2013.79
Keywords
This article is cited by
-
BH3-mimetics: recent developments in cancer therapy
Journal of Experimental & Clinical Cancer Research (2021)
-
BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics
Cell Death & Differentiation (2020)
-
Mcl-1 Inhibitor Induces Cells Death in BRAF-Mutant Amelanotic Melanoma Trough GSH Depletion, DNA Damage and Cell Cycle Changes
Pathology & Oncology Research (2020)
-
Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477
Cell Death & Disease (2019)
-
BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL
Cell Death & Differentiation (2019)
